PolyActiva is focused on providing unique biodegradable implants with sustained drug delivery to improve patient outcomes and quality of life for patients suffering from ophthalmic diseases such as glaucoma.

PolyActiva

PolyActiva | 1,034 followers on LinkedIn. Enabling Drug Delivery from Medical Devices | PolyActiva is an innovative clinical-stage ophthalmology company with a unique proprietary polymeric prodrug technology that enables site-specific, precise and controlled drug delivery to the eye.

With the PolyActiva technology, exceptional zero-order release profiles are achieved over treatment periods ranging from 6 to 12 months.

Our mission is to become a leader in ophthalmic medicine by providing unique biodegradable implants with sustained drug delivery to improve patient outcomes and quality of life.

CEO at PolyActiva Pty Ltd

Vanessa Waddell

Nonclinical and Formulation Leader at PolyActiva | Pharmacist | Polymeric Drug Delivery | Physical Pharmacy

Igor Chekhtman

Analytical R&D Team Leader with PolyActiva (Biotechnology)

Tiffany Reeves

Head, Product Development and Technical Affairs at PolyActiva

Justine Walter

Thank you Brandon Capital , along with all of our other incredible shareholders, for supporting us through these vital stages of development! Support from local VCs and investors allows Australian-made, innovative products like ours the chance to capture markets globally! Something we’ll be focussing on in our pivotal late-stage clinical trials early 2025 under our IND submission to the FDA #glaucoma #investment #biotechnology #innovation

👁️ PolyActiva is thrilled to report our latest clinical data from our Phase 2a trial testing PA5108, a 6-month sustained-release ocular implant for patients suffering from glaucoma. PA5108 has successfully met the safety and efficacy endpoints in the repeat-dose cohort, demonstrating a statistically significant change from baseline in intraocular pressure (IOP) at weeks 12, 21, 33 and 42 (p<0.0001). Clinically meaningful IOP reductions of 26-35% were observed over 48 weeks. Most importantly to us, the implant was found to be safe and generally well tolerated by trial participants following repeat-dosing over 48 weeks of monitoring! These results demonstrate that PA5108 could be used to treat patients' glaucoma long-term over multiple doses without the compliance and dosing issues that come with drop therapy. PolyActiva is scaling up our manufacturing capabilities to support the commencement of late-stage clinical trials in early 2025, with trials to be conducted under an IND submission to the FDA. Read the full statement here: https://lnkd.in/gvB4QRhW #Glaucoma #DrugDelivery #Biotechnology #Innovation

Vanessa Waddell presents PolyActiva at #AusBioInv highlighting their implantable treatment for glaucoma.

Lis Boyce

Great to catch up with Vanessa Waddell CEO of PolyActiva at the AusBiotech #AusBioInv Exciting new data on the safe and effective glaucoma treatment developed here in Australia. #Ausbiotech24 Chris Nave Chris Smith Bob Soh Brandon Capital

MARILYN JONES

🚨 PolyActiva 's CEO, Vanessa Waddell , and our Head of Product Development & Technical Affairs, Justine Walter , will both be attending AusBiotech 2024 starting tomorrow at Melbourne's Convention & Exhibition Centre. With so many incredible industry leaders and experts attending, we can't wait to see what the next few days has in store for us! If you're in the area and would like to catch up with our team, reach out and say hello 👋 We'd love to fill you in on what we've been up to! #Ausbiotech2024 #Innovation #Biotech #Investment

PolyActiva is excited to announce that our CEO, Vanessa Waddell , will be presenting at #AusBioInvest24 on 29 October in the 4:00pm – 4:55pm session. Vanessa will be presenting our latest 48-week clinical data from our Phase 1b/2a clinical trial, which demonstrates both the safety of repeat-dosing with our PA5108 Ocular Implant, and sustained reduction in intraocular pressure in this repeat-dose cohort out to 48 weeks. This data backs our goal of providing patients suffering from glaucoma a long-term sustained-release alternative solution to drop therapy. Thank you AusBiotech for this opportunity, we can’t wait to share these results with you and what we have on the horizon. #AusBio #AusBioInv24 #Glaucoma #Innovation

We're incredibly proud of our CEO Vanessa Waddell 's recent presentation at Eyecelerator @ AAO2024 last week. Vanessa got the chance to present our new 48-week clinical data from our Phase 1b/2a clinical trial, which demonstrates both the safety of our PA5108 after repeat-dosing, as well as a sustained reduction in intraocular pressure out to 48 weeks. These results are the culmination of over a decade of research and work by our incredible team, with help from countless other consultants and clinicians along the way. It's exciting to be another step closer to providing patients suffering from glaucoma a safe and effective sustained-release implant as an alternative to drop therapy! #Glaucoma #Biotech #Innovation #AAO2024

PolyActiva 's Nonclinical & Formulation Leader Dr. Igor Chekhtman , and Commercial Operations & BD Associate Alexander Goulsbra attended the BioConnections 2024 Conference last week. Thank you to Informa Australia for putting together such an insightful conference with incredible keynote speakers and excellent panel discussions! It was also great to catch up with Camille Shanahan from Jumar Bioincubator , where PolyActiva is utilising their state-of-the-art laboratories to continue manufacturing our ocular implants locally, ready for our upcoming clinical trial program. #BioConnexAus #Glaucoma #Innovation #Incubator #Biotech

The PolyActiva Polymer Chemistry Team has had a busy week setting up the cleanrooms at Jumar in Melbourne so we can keep the manufacture of our phase 1 clinical trial material local. With limited options for manufacturing our ocular implants, access to Jumar’s state-of-the-art laboratories provides us with the opportunity to build our ocular implant manufacturing capabilities internally rather than having to go offshore. It’s an exciting time, and we’re also looking forward to joining a community fostering the next generation of Australian biotech

PolyActiva 's Head of Polymers & Medical Devices, Dr. David Valade will be presenting at PharmOut 's Pharma & Device Forum 2024 this Friday 24 May at the Melbourne Exhibition and Convention Centre in Melbourne, Australia. David will be discussing the hurdles PolyActiva has overcome to manufacture our unique sustained-release, biodegradable ocular implants for use in our clinical trial programs. If you're attending this event, you can catch David's presentation in Room 103 from 2:00pm - 2:30pm AEST. Come and say hi! #Glaucoma #Pharmaceutical #Manufacturing #Innovation

Viewport Meta

IPhone / Mobile Compatible

Apple Mobile Web Clips Icon

Google Font API

Content Delivery Network

WordPress

Font Awesome

Organization Schema

reCAPTCHA

Sitelinks Search Box

Interim CEO

Head, Product Development and Technical Affairs

Senior CMC Project Manager

Angela Liakatos

Commercial Operations and Business Development Associate

Alexander Goulsbra

Senior Development Scientist

Asha D'Souza

Engineering

Darran Loits

Operations

David Valade

R&D Analytical Scientist

Rafeed Ferdous

Senior Research Scientist

Sarah Ng

Liddy McCall

James Williams

Chris Nave

Chairman and Non-Executive Director

Russell Tait

CEO & Co-Founder

Andrew Donohue

Head of Organic Chemistry

Barrie Finnin

Non-Executive Director

Australasia Companies (Top 10K)

Medical Early Stage Companies With More Than 10 Employees

Oceania Early Stage Companies With More Than 10 Employees

Australasia Startups

PolyActiva has developed proprietary drug-polymer conjugate technology that enables site-specific drug delivery from medical device components such as ocular implants, intra-articular gel implants, and drug-eluting fibers.

Medical Research Future Fund (MRFF)

Grant - PolyActiva

Yuuwa Capital

Series B - PolyActiva

Series A - PolyActiva

Melbourne

Victoria

Australia

Oceania

Topical glaucoma medication for glaucoma management ...

Ocular Hypertension Market Size and Share to Increase by ...

Polyactiva’s ocular implant shows sustained drug delivery for glaucoma

Open-Angle Glaucoma Market Size and Share to Accelerate ...

PolyActiva appoints Tracy Valorie, ophthalmic industry expert and former Bausch + Lomb executive, to its Board of Directors

Brandon Capital launches $200M venture fund for life science startups, backed by Australian super funds

Brandon Capital Closes Life Science Venture Capital Fund at AU$200M

Brandon Capital Partners Raises AU$200M New MRCF Fund

A platform for precise and controlled drug delivery using biodegradable implants, designed to improve patient outcomes in ophthalmic diseases.

An ocular implant in Phase II development aimed at reducing intraocular pressure in glaucoma and ocular hypertension patients, providing sustained drug release for six months.

An ocular implant in Phase I development intended to reduce the risk of postoperative bacterial endophthalmitis following cataract surgery, offering sustained drug release and biodegradability.

A pipeline of ocular implants utilizing Prezia technology to provide biodegradable, sustained-release treatments for various ocular diseases.

news impact assignment basic	general
public peers	general	Nov 19, 2024 9:17 PM	97f772f8
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 19, 2024 9:17 PM	37d88f2b
crunchbase trigger	general	Nov 19, 2024 9:17 PM	54ad6d48
crunchbase profile	general	Nov 20, 2024 8:52 AM	c2c75b36
li profile	general	Nov 19, 2024 9:17 PM	986b3cf8
translate crunchbase fundingrounds	general	Nov 20, 2024 9:51 AM	38c2eb0d
peers	general	Nov 19, 2024 9:17 PM	49c9d46e
news basic	general	Nov 19, 2024 9:17 PM	918a095d
bundesanzeiger	filings
financials download nd	financials
private financials	financials

POLY

COM:POLYACTIVA

PolyActiva